Sold out over a year ago. Managed to double what I pulled out, but still a very long way off what I lost on this stock.After money, the biggest thing you'll lose on this stock is time.
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%